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Importance—Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria 
during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the 
standard 2-dose regimen. However, 2 doses may not provide protection during the last 4 to 10 
weeks of pregnancy, a pivotal period for fetal weight gain.
Objective—To perform a systematic review and meta-analysis of trials to determine whether 
regimens containing 3 or more doses of sulfadoxine-pyrimethamine for intermittent preventive 
therapy during pregnancy are associated with a higher birth weight or lower risk of low birth 
weight (LBW) (<2500 g) than standard 2-dose regimens.
Data Sources and Study Selection—ISI Web of Knowledge, EMBASE, SCOPUS, PubMed, 
LILACS, the Malaria in Pregnancy Library, Cochrane CENTRAL, and trial registries from their 
inception to December 2012, without language restriction. Eligible studies included randomized 
and quasi-randomized trials of intermittent preventive therapy during pregnancy with sulfadoxine-
pyrimethamine monotherapy.
Data Extraction—Data were independently abstracted by 2 investigators. Relative risk (RR), 
mean differences, and 95% CIs were calculated with random-effects models.
Results—Of 241 screened studies, 7 trials of 6281 pregnancies were included. The median birth 
weight in the 2-dose group was 2870 g (range, 2722–3239 g) and on average 56 g higher (95% CI, 
29–83 g; I2=0%) in the ≥3-dose group. Three or more doses were associated with fewer LBW 
births (RR,0.80; 95% CI, 0.69–0.94; I2=0%), with a median LBW risk per 1000 women in the 2-
dose group (assumed control group risk) of 167 per 1000 vs 134 per 1000 in the ≥3-dose group 
(absolute risk reduction, 33 per 1000 [95% CI, 10–52]; number needed to treat=31). The 
association was consistent across a wide range of sulfadoxine-pyrimethamine resistance (0% to 
96% dihydropteroate-synthase K540E mutations). There was no evidence of small-study bias. The 
≥3-dose group had less placental malaria (RR,0.51; 95% CI, 0.38–0.68; I2=0%, in 6 trials, 63 vs 
32 per 1000; absolute risk reduction,31 per 1000 [95% CI, 20–39]). In primigravid plus 
secundigravid women, the risk of moderate to severe maternal anemia was lower in the ≥3-dose 
group (RR,0.60; 95% CI, 0.36–0.99; I2=20%; in 6 trials, 36 vs 22 per 1000; absolute risk 
reduction,14 per 1000 [95% CI, 0.4–23]). There were no differences in rates of serious adverse 
events.
Conclusions and Relevance—Among pregnant women in sub-Saharan Africa, intermittent 
preventive therapy with 3 or more doses of sulfadoxine-pyrimethamine was associated with a 
higher birth weight and lower risk of LBW than the standard 2-dose regimens. These data provide 
support for the new WHO recommendations to provide at least 3 doses of intermittent preventive 
therapy during pregnancy at each scheduled antenatal care visit in the second and third trimester.
In Areas Of Stable Malaria Transmission in sub-Saharan Africa, Plasmodium falciparum 
infection in pregnant women is associated with maternal anemia and low birth weight 
(LBW) (<2500 g),1–3 especially among primigravida and secundigravida and human 
immunodeficiency virus (HIV)–infected women.1 The World Health Organization (WHO) 
recommended intermittent preventive therapy during pregnancy, consisting of at least 2 full 
treatment doses of sulfadoxine-pyrimethamine for HIV-negative women and at least 3 doses 
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for HIV-positive women not receiving cotrimoxazole, administered presumptively in the 
second and third trimesters at least 1 month apart.4,5 Each dose suppresses or clears any 
existing asymptomatic infections from the placenta and provides up to 6 weeks of 
posttreatment prophylaxis.4,6 Although the standard 2-dose regimen provides at most 12 
weeks of prophylaxis,6 it has been shown to be effective in reducing LBW7–13 and was 
adopted by 31 of 37 endemic countries in Africa with a policy for intermittent preventive 
therapy during pregnancy; the remaining countries use a 3-dose or monthly regimen.14 
Nevertheless, reinfections are common with the 2-dose regimen, especially among women 
who complete their last dose early in the third trimester.8,9 A previous meta-analysis7 of 3 
trials confirmed that additional doses of sulfadoxine-pyrimethamine may add benefit over 2 
doses among HIV-infected primigravida plus secundigravida (G1–G2 women), but there 
was insufficient evidence on HIV-negative women or intermittent preventive therapy during 
pregnancy when used in combination with insecticide-treated nets. Furthermore, increasing 
sulfadoxine-pyrimethamine resistance, which results in a progressive decrease of the 
duration of the prophylactic effect,6 may also require more frequent dosing.7
The objective of this analysis was to evaluate whether 3 or more doses of intermittent 
preventive therapy during pregnancy with sulfadoxine-pyrimethamine are associated with 
higher birth weight or a lower risk of LBW than the current standard 2-dose regimen and to 
examine whether this is moderated by sulfadoxine-pyrimethamine resistance, HIV status, 
gravidity, or use of insecticide-treated nets.
METHODS
Eligibility Criteria
Study inclusion criteria, outcomes, and methods for the analysis were prespecified in the 
protocol. Studies had to be quasi-randomized or randomized controlled trials conducted with 
pregnant women living in sub-Saharan Africa, comparing the standard 2-dose regimen with 
sulfadoxine-pyrimethamine with a regimen of intermittent preventive therapy during 
pregnancy consisting of 3 doses or monthly dosing. Studies or study groups that combined 
sulfadoxine-pyrimethamine with other antimalarial drugs, such as artemisinin derivatives or 
azithromycin, or other interventions, such as screening for malaria, were excluded. Use of 
mosquito nets was not an exclusion criterion. Trial inclusion was unrestricted by gravida 
group, HIV status, and type of outcomes reported.
Study Selection
Studies were identified by searching PubMed, SCOPUS, ISI Web of Knowledge, EMBASE, 
LILACS, Cochrane CENTRAL, the Malaria in Pregnancy Library,15 WHO’s International 
Clinical Trials Registry Platform, and the Cochrane Central Register of Controlled Trials 
from their inception to December 11, 2012, without language restrictions; scanning 
reference lists of articles; and consultation with experts in the field (see eFigure 1 and 
eMethods, available at http://www.jama.com). For trial selection, 2 authors (K.K. and 
A.M.v.E.) independently screened and assessed trials for eligibility and final inclusion in the 
analysis in a standardized manner. Disagreement between reviewers was resolved through 
consensus after discussion and consultation with the senior author (F.O.t.K.).
Kayentao et al. Page 3













Data Collection and Analysis
Data extraction was conducted independently by 2 unblinded investigators (K.K. and 
A.M.v.E.) using pre-tested standardized data extraction forms. Authors of primary studies 
were contacted for missing information or if reported data did not fit the required format. 
For each study, the following information was extracted: first author, publication year, year 
of study start and end, study design, randomization procedures, inclusion criteria (eg, any 
restrictions by gravidity, age, or HIV status), insecticide-treated net or bed net use, folate 
supplementation and dosage, local malaria transmission, details of study groups, number of 
women enrolled, and outcomes assessed, including adverse events overall and stratified by 
subgroup. The Cochrane Collaboration’s tool for assessing the risk of bias16 was used to 
determine the quality of included trials as low (high risk of bias), high (low risk of bias), or 
unclear. Uncertainties were resolved by consensus and by contacting the corresponding 
authors.17
Time- and location-matched data on molecular resistance to sulfadoxine-pyrimethamine 
were obtained from published articles, as described previously,18 and through 
correspondence with the authors of the trials. The prevalence of the K540E mutation in the 
dihydropteroate synthase (DHPS) gene was used as a proxy for the prevalence of the 
combined dihydrofolate reductase DHFR (N51I, C59R, and S108N)/DHPS (A437G, 
K540E) quintuple genotype that is strongly associated with treatment failure of sulfadoxine-
pyrimethamine.19
Synthesis
The primary outcome measures were LBW and mean birth weight. Secondary outcomes 
included maternal hemoglobin level, maternal anemia (hemoglobin level <11 g/dL) and 
moderate to severe anemia (defined by the individual trials as hemoglobin level <6, 7, or 8 
g/dL) at term or delivery, maternal malaria infection (peripheral blood) at delivery, placental 
malaria infection (all species), preterm delivery (<37 weeks’ gestation), spontaneous 
miscarriage, stillbirth, and neonatal death (death within 0–27 days in live-born infants). All 
analyses were stratified a priori by HIV status and gravidity status (G1–G2 vs ≥G3 
pregnancies [multigravida]), with the aim to provide independent subgroup estimates and 
overall estimates of the pooled data.
We used both random-effects (primary method) and fixed-effects models to calculate the 
summary relative risks (RRs) for dichotomous outcomes (Mantel-Haenszel) or differences 
in means for continuous outcomes (inverse variance) and we prespecified that any 
heterogeneity would be investigated by subgroup analysis. To provide estimates of absolute 
risk and effect, values for the assumed control-group risk in 2-dose recipients and the 
corresponding intervention-group risk and 95% CI in ≥3-dose recipients were computed as 
assumed control-group risk = median risk (expressed per 1000 women) across the included 
trials in the 2-dose group; corresponding intervention-group risk=assumed control-group 
risk ×RR (95% CI), where the RR was taken from random-effects models.20 The absolute 
risk reduction was calculated as the assumed control-group risk×(1−RR) and expressed per 
1000 women. Similar methods were used with the lower and upper CI of the RR to obtain 
the 95% CI of the absolute risk reduction. The number needed to treat (NNT) for LBW (the 
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primary end point) was computed as NNT = 1/(assumed control-group risk×[1−RR]).20 For 
the continuous end points, the observed median birth weight or hemoglobin concentration in 
the 2-dose group was reported as the assumed control-group median. The corresponding 
value in ≥3-dose recipients was expressed as the corresponding intervention-group median 
and 95% CI, which were computed as the assumed control-group median+mean difference 
(95% CI).
Heterogeneity was quantified with the I2 statistic and χ2 test.21 The Deeks and Higgens 
method was used to test for heterogeneity between the different summary estimates across 
subgroups.22 Publication and small-study bias was assessed by visual inspection of funnel 
plots and the Harbord test. To evaluate the change in pooled summary estimates for the RR 
with addition of new evidence, we created cumulative meta-analysis plots.23 Prespecified 
sensitivity analysis for the primary outcomes was performed by excluding all studies that 
were scored as low quality for allocation concealment or other sources of bias.16 Further 
sensitivity analysis was conducted to test the effect of each study on the pooled estimates 
and heterogeneity by removing one study at a time from the meta-analysis. We used P <.05 
to indicate statistical significance (2-sided tests). Data were analyzed with Review Manager 
version 5.2, GradePro version 3.6, and Stata version 12.
RESULTS
Studies and Outcomes
A total of 241 studies were screened, and 7 trials including a total of 6281 pregnancies were 
included (eFigure 1),9,12,24–29 one of which was unpublished29 (Table 1). Authors of all 
primary studies provided further unpublished information where available. Five trials 
compared monthly sulfadoxine-pyrimethamine against the standard 2-dose regimen and the 
remaining 2 compared 3- vs 2-dose intermittent preventive therapy during pregnancy with 
sulfadoxine-pyrimethamine.9,28 Sulfadoxine-pyrimethamine intake was supervised in all 
trials.
Three trials in Kenya and Malawi involved both HIV-infected and uninfected 
women,12,24,26 and 1 trial in Zambia involved HIV-infected women only.25 In 3 other trials, 
the HIV status was unknown,9,28,29 2 of which were from areas with very low HIV 
prevalence among pregnant women (1% in Burkina Faso and 1.3% in Mali)9,28; results were 
therefore pooled with those of the HIV-negative women. The third trial from Tanzania29 
was conducted in an area with high HIV prevalence and analyzed as a separate “HIV status 
unknown” stratum. Two of the 7 trials were considered of low quality (eFigure 2), including 
a trial in Burkina Faso, in which two-thirds of participants did not receive the intended 
regimen.28 The other study was a quasi-randomized trial12 conducted before the 
introduction of the Consolidated Standards of Reporting Trials (CONSORT) guidelines for 
clinical trials37 (Table 1).
Primary Outcomes: Birth Weight
Women in the ≥3-dose group had fewer infants with LBW (random-effects model RR=0.80; 
95% CI, 0.69–0.94; P =.006; I2=0%) (Figure 1), corresponding to an RR reduction (RR 
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reduction = 100% =[1 −RR]) of 20% (95% CI, 6–31). The absolute risk reduction was 33 
per 1000 women (95% CI, 10–52), from a median risk of 167 per 1000 in the 2-dose group 
(assumed control-group risk) to 134 per 1000 in the ≥3-dose recipients (NNT=31). The 
median birth weight in the 2-dose group was 2870 g (range, 2722–3239 g) and on average 
56 g (95% CI, 29–83 g) higher in the ≥3-dose group (Figure 2, Table 2). Analyses by 
gravida and HIV subgroup showed that the mean difference in birth weight was statistically 
significant in HIV-negative women (random-effects mean difference=58 g; 95% CI, 26–90 
g), HIV-positive women (mean difference=97 g; 95% CI, 22–172) (Table 2), G1–G2 women 
(mean difference=57 g; 95% CI, 22–93 g) (eTable 1), and multigravida (mean difference=53 
g; 95% CI, 11–95 g) (eTable 2) (between-subgroup difference, I2=0%; P =.53) (Figure 2). 
The RR estimates for LBW, however, were significant only in HIV-negative women (RR = 
0.77 [95% CI, 0.63–0.94] [Table 2]; assumed control-group risk=106 per 1000; absolute risk 
reduction=24 per 1000 [95% CI, 6–39]; NNT = 42) and G1–G2 women (RR=0.80 [95% CI, 
0.68–0.95] [eTable 1]; assumed control-group risk=181 per 1000; absolute risk 
reduction=36 per 1000 [95% CI, 9–58]; NNT=28) but not in HIV-positive women (RR=0.86 
[95% CI, 0.53–1.39] [Table 2]; assumed control-group risk = 175 per 1000; absolute risk 
reduction=24 per 1000 [95% CI, −68 to 82]; NNT=42) or multigravida (RR = 0.79 [95% CI, 
0.49–1.27] [eTable 2]; assumed control-group risk=78 per 1000; absolute risk reduction=16 
per 1000 [95% CI, −21 to 40]; NNT = 63). The difference in the RR estimates between the 
subgroups was not significant (between-subgroup difference I2= 0%; P = .96) (Figure 1). 
The results of fixed-effects models overall and by gravidity or HIV groups were mostly 
identical or very similar (eTable 3).
There was no evidence for publication bias after visual inspection of funnel plots or with the 
Harbord modified test for small-study effects (P =.72) (eFigure 3). Cumulative meta-
analysis, ordered by publication date, showed that a significant association with LBW 
emerged with the addition of new evidence from trials reported since 2010 (eFigures 4 and 
5). Sensitivity analysis showed that after removal of both low-quality studies,12,28 the point 
estimates for LBW and mean birth weight were RR=0.76 (95% CI, 0.61–0.93), I2=16%; and 
mean difference=62 g (95% CI, 29–95 g), I2=0%. Removal of any individual trial also had 
relatively little effect and pooled results remained statistically significant at P <.05 for all 7 
analyses with fixed-effects models and at P =.06 with random-effects models (eFigures 6 
and 7).
Secondary Outcomes
The median maternal hemoglobin level at term in the 2-dose group was 10.9 g/dL (range, 
9.7–11.6 g/dL), and this was on average 0.13 g/dL higher (95% CI, 0.03–0.22 g/dL) in the 
≥3-dose group (Table 2, eFigure 8). This group had a lower risk of moderate to severe 
maternal anemia, but this was evident only in G1–G2 women (RR=0.60 [95% CI, 0.36–
0.99]; I2=20%) (eTable 1), not overall (RR = 0.73 [95% CI, 0.48–1.11]; I2=15%) (Table 2 
and eFigure 9). Women in the ≥3-dose group were approximately half as likely to have 
placental malaria (6 studies) compared with those in the 2-dose group, regardless of HIV 
status (RR=0.51 [95% CI, 0.38–0.68]; I2=0%) (Table 2, eFigure 10), but this was evident 
only in G1–G2 women (RR = 0.50 [95% CI, 0.35–0.70]; I2=0%) (eTable 1), not in 
multigravida (RR = 0.71 [95% CI, 0.26–1.95]; I2=21%) (eTable 2). Similarly, ≥ 3 doses 
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were associated with less peripheral (maternal) malaria (RR=0.68 [95% CI, 0.52–0.89]; 
I2=47%) (Table 2), but this was evident in G1–G2 women only (RR=0.54 [95% CI, 0.37–
0.80]; I2= 56%) (eTable 1), not in multigravida (RR = 0.97 [95% CI, 0.75–1.24]; I2= 0%) 
(eTable 2). No difference in preterm delivery was detected (RR = 0.95 [95% CI, 0.80–1.12]; 
I2= 35%) or in the number of stillbirths (RR=1.14 [95% CI, 0.85–1.55]; I2=0%), 
miscarriages (RR=1.43 [95% CI, 0.88–2.33]; I2= 0%), or neonatal deaths (RR = 0.88 [95% 
CI, 0.57–1.35]; I2=0%) (Table 2).
Stratified Analysis for LBW and Mean Birth Weight
There was no clear correlation between resistance level and the strength of the association 
between treatment regimen and LBW or mean birth weight; the point estimates were similar 
in areas with less than 50% DHPS-K540E mutations (5 trials) and areas with 50% or more 
DHPS-K540E (2 trials) (eFigures 11 and 12). There was also no evidence that intensity of 
malaria transmission or the median number of sulfadoxine-pyrimethamine doses in the ≥3-
dose group modified the association (P >.17 for all tests for subgroup differences). There 
was no clear difference in the association between the dose group and the risk of LBW or 
mean birth weight in the 2 trials that used high-dose folate supplementation (5 mg/d)12,25 
(which has since been contraindicated) vs the standard dose (0.25–0.5 mg/d). Three studies 
reported results stratified by insecticide-treated net use9,26,29; the associations with LBW 
and mean birth weight were statistically significant in the nonusers only. There was no 
evidence for an association with LBW in insecticide-treated net users (eFigures 11 and 12).
Adverse Events
The risks of neonatal icterus and congenital malformation were comparable between the 
groups, as were the number of adverse events in the mother. One study reported a case of 
Stevens-Johnson syndrome, which occurred in the 3 or more dose group, 3 weeks after the 
first dose (Table 3).25
COMMENT
This meta-analysis of 7 trials demonstrated that regimens of intermittent preventive therapy 
during pregnancy consisting of ≥3 doses of sulfadoxine-pyrimethamine were well tolerated 
and, compared with the standard 2-dose regimen, were associated with higher mean birth 
weight, less LBW, and less placental and maternal malaria at delivery. The ≥3-dose regimen 
was also associated with slightly higher mean maternal hemoglobin levels at term overall, 
but a significant association with moderate to severe maternal anemia was observed only in 
G1–G2 women. The associations with birth weight were consistent across trials despite 
variations in study design, malaria endemicity, and the degree of sulfadoxine-pyrimethamine 
resistance. Although the number of trials was limited, there was no suggestion of publication 
or other small-study bias. There was also no suggestion that the results were affected by the 
weight of a single influential study. Two of the trials were classified as low quality, but 
sensitivity analysis indicated that their effect on the overall pooled estimate for LBW was 
minor. The consistency of these findings across the trials suggests the results are 
generalizable.
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Although the summary point estimates of the association with mean birth weight were 
modest (56-g difference overall and 67 g among HIV-negative G1–G2 women), these were 
associated with clinically relevant changes in the risk of LBW, particularly among HIV-
negative G1–G2 women (RR reduction=25%) (eTable 1). These estimates were comparable 
to that reported in previous studies for 2-dose intermittent preventive therapy during 
pregnancy relative to none (mean difference=79 g; RR reduction=29%) and for insecticide-
treated nets alone (mean difference=55 g; RR reduction=23%).7,38 The magnitude of the 
observed association is remarkable, given that approximately 28% of women were protected 
by insecticide-treated nets in these 7 trials and considering that the control group benefited 
from protection of the 2-dose intermittent preventive therapy during pregnancy with 
sulfadoxine-pyrimethamine. The association mainly reflects an association with fetal 
growth, rather than with preterm delivery, and indicates that more complete protection in the 
second and third trimesters, including the last 6 to 10 weeks of pregnancy, may be pivotal 
for fetal growth. This result is consistent with observations in healthy pregnancies, which 
show that of the total fetal weight gain, 28% and 55% of it occurs during the last 6 and 10 
weeks of pregnancy, respectively.39
Although the lack of heterogeneity across the sulfadoxine-pyrimethamine resistance range is 
encouraging, it does not imply that sulfadoxine-pyrimethamine efficacy is unaffected at 
higher levels of resistance. A possible explanation is that the extra doses compensate for any 
reductions in efficacy of the 2-dose regimen resulting from a progressive decrease of the 
duration of posttreatment prophylaxis.
The association with placental infections is an expected outcome because the 3 or more dose 
group received their last dose on average 1 month closer to delivery and is likely to reflect 
clearance of existing infections near term and prevention of new infections by the extra 
period of prophylaxis. However, the association with mean birth weight among multigravida 
was unexpected because most multigravida in endemic countries have acquired a pregnancy-
specific protective immunity during exposures in previous pregnancies. Overall, the 
evidence for a beneficial association in multigravida was weak, and the finding in this study 
may therefore reflect a chance observation (eg, because of multiple comparisons) or 
mechanisms other than the prevention of malaria. Although the point estimates for LBW 
(RR reduction 21%) and placental malaria (RR reduction 29%) were in the same direction as 
those observed in primigravida and secundigravida, none were statistically significant and 
there was no suggestion that ≥3 doses were associated with less maternal malaria or 
moderate to severe anemia. On the other hand, the lack of significant association with LBW 
may reflect lack of power because only 4 of the 7 studies included multigravida.
Our meta-analysis has some limitations. First, although all trials were designed to 
standardize the number of visits and antenatal care (eg, hematinic supplementation) between 
the 2 groups, in one trial in Tanzania the women in the ≥3-dose group had on average 1 
extra visit compared with the 2-dose group and thus potentially better antenatal care.29 
However, exclusion of this study in the sensitivity analysis did not change the conclusion 
(eFigures 6 and 7). Second, only 1 of the 7 trials was placebo controlled, which may have 
biased the results and affected some outcomes because of lack of expectations in a 2-dose 
group or differential behaviors across intervention groups. We did not use blinding in the 
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selection, evaluation, and data abstraction phases, and because the authors were familiar 
with all included studies, this could have introduced bias.40 Third, none of the trials were 
conducted in regions where additional DHFR 164L or DHPS 581G mutations are prevalent, 
as reported from parts of Rwanda, Uganda, and northern Tanzania, conferring the highest 
level of sulfadoxine-pyrimethamine resistance.18,41–43 Last, only 3 trials reported results 
stratified by insecticide-treated net use, limiting our evaluation of the potential modifying 
role of insecticide-treated nets. In this smaller subgroup of studies, significant associations 
with LBW and mean birth weight were observed among the non-users of insecticide-treated 
nets only, consistent with results of previous evaluations of 2-dose intermittent preventive 
therapy during pregnancy against placebo.15,44,45
Only 1 serious cutaneous reaction was reported in the current meta-analysis involving 13 
554 sulfadoxine-pyrimethamine treatments among 6281 pregnancies, and this occurred in an 
HIV-positive woman 3 weeks after she received her first dose of sulfadoxine-pyrimethamine 
for intermittent preventive therapy during pregnancy.25 We found no indication that more 
frequent dosing (ie, resulting in doses administered closer to delivery) was associated with 
increased risk of neonatal jaundice, the main safety signal of interest in neonates. 
Sulfonamides have the potential to displace unconjugated bilirubin from albumin, which 
could increase a newborn’s risk of kernicterus if received near delivery. Our observations, 
combined with the evidence reviewed by Peters et al44 from the experience with 
sulfonamides for rheumatic fever prophylaxis, urinary tract infections, and congenital 
toxoplasmosis (which involve higher doses and prolonged use of sulfadoxine-
pyrimethamine), suggest that concerns regarding kernicterus should not restrict the use of 
monthly sulfadoxine-pyrimethamine for intermittent preventive therapy during pregnancy. 
There was no indication that ≥3-dose regimens increased or reduced the risk of stillbirth or 
neonatal death. The risk of spontaneous miscarriages in G1–G2 women was higher among 
the 3-dose group (RR=1.78, P =.046 with fixed-effects models and RR = 1.75, P = .06 with 
random-effects models). These miscarriages, however, were not associated with the third 
dose because in 3 of the 4 trials that contributed 80% of the study weight, they occurred 
before 28 weeks of gestation when the third dose had not yet been provided.9,24,28 In the 
fourth trial, the risk of miscarriage was 2.0% with a monthly regimen, higher than the 1.1% 
in the 2-dose group but similar to the 2.3% in a third control group consisting of women 
randomized to passive case detection only instead of intermittent preventive therapy during 
pregnancy.12
Since the strategic framework for the control of malaria in pregnancy in sub-Saharan Africa 
was first developed, at least 3 doses of sulfadoxine-pyrimethamine for intermittent 
preventive therapy during pregnancy has been recommended by WHO for HIV-infected 
women or for all women in high-HIV-prevalence areas (>10%) where screening for HIV is 
not conducted. Some countries, such as Cameroon,45 Ghana, Zambia, and Zimbabwe, 
selected 3 doses of sulfadoxine-pyrimethamine in their policy for all pregnant women, but 
most other countries, including many high-HIV-prevalence countries, implemented the 2-
dose regimen and use cotrimoxazole for HIV-infected women.14 However, more recently 
other countries, including Kenya and Malawi, implemented a monthly regimen among HIV-
negative women mainly because of concerns about sulfadoxine-pyrimethamine resistance 
Kayentao et al. Page 9













and for pragmatic reasons to minimize the risk for missed opportunities to deliver a second 
dose46 and to achieve better alignment with WHO’s focused antenatal care schedule (a goal-
oriented antenatal care approach consisting of 4 visits providing essential evidence-based 
interventions). In southern Malawi, this has resulted in a marked increase in the uptake of 2 
or more doses of sulfadoxine-pyrimethamine.47
Our cumulative meta-analysis showed that, with the accumulation of results from the 4 most 
recent trials reported since 2010, evidence has emerged that 3-dose or monthly sulfadoxine-
pyrimethamine for intermittent preventive therapy during pregnancy was associated with a 
higher birth weight and lower risk of LBW than the standard 2-dose regimens among 
pregnant women in sub-Saharan Africa. These data provide support for the new WHO 
recommendation that intermittent preventive therapy during pregnancy with sulfadoxine-
pyrimethamine be provided at each scheduled focused antenatal-care visit in the second and 
third trimesters in all settings in which intermittent preventive therapy during pregnancy 
with sulfadoxine-pyrimethamine is recommended.48 Future research should focus on how 
best to implement the updated WHO guidelines for intermittent preventive therapy during 
pregnancy with sulfadoxine-pyrimethamine48 and specifically their integration with focused 
antenatal care. Continued monitoring of the association between population-level 
sulfadoxine-pyrimethamine resistance and the effectiveness of intermittent preventive 
therapy during pregnancy is required.
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Meta-analysis of the Risk of Low Birth Weight in Trials Comparing the Standard 2-Dose vs 
3 or More Doses of Intermittent Preventive Therapy During Pregnancy With Sulfadoxine-
Pyrimethamine
G1–G2 indicates first and second pregnancies; ≥G3, 2 or more previous pregnancies; HIV, 
human immunodeficiency virus; RR, relative risk. P values after the I2 statistics represent 
the χ2 test for heterogeneity. Dersimonian-Laird method used to calculate random-effects 
models; Mantel-Haenszel for fixed-effects models. Weights are from random-effects 
analysis. Data marker sizes indicate the weight applied to each study with random-effects 
meta-analysis. Test for subgroup differences: , P= .96, l2= 0.0%.
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Meta-analysis of Mean Birth Weight in 7 Trials Comparing the Standard 2-Dose vs 3 or 
More Doses of Intermittent Preventive Therapy During Pregnancy With Sulfadoxine-
Pyrimethamine
G1–G2 indicates first and second pregnancies; ≥G3, 2 or more previous pregnancies; HIV, 
human immunodeficiency virus status. P values after the I2 statistics represent the χ2 test for 
heterogeneity. Dersimonian-Laird method used for random-effects models; inverse-variance 
method used in the fixed-effects models. Weights are from random-effects analysis. Data 
marker sizes indicate the weight applied to each study with random-effects meta-analysis. 
Test for subgroup differences: , P= .53, l2= 0.0%.
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